NASDAQ$DAWN
Day One Biopharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Day One reported Q4 2023 financial results and corporate progress.
Day One Biopharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting the upcoming PDUFA date for tovorafenib and continued advancement of the Phase 3 front-line trial. The company ended the year with $366.3 million in cash, providing runway into 2026.
- PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024.
- Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine.
- Ended 2023 with $366.3 million in cash, cash equivalents and short-term investments providing runway into 2026.
- Day One continued its commercial preparedness for the approval and launch of tovorafenib with the hiring of 18 sales representatives in the U.S.
Headline financials
Revenue & EPS history
Day One · Revenue · Quarterly
$0
Forward guidance
Day One anticipates a monumental year ahead with the upcoming PDUFA date for tovorafenib and continues to advance its Phase 3 front-line trial.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-1.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+1.2%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+23.6%
Q2 2022
Best reaction
-16.6%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -9.2% | -13.9% | +78.0% | |
| Q3 2025 | +0.0% | +3.7% | +34.8% | |
| Q2 2025 | -15.4% | -14.2% | +9.7% | |
| Q1 2025 | -9.6% | -5.9% | +2.9% | |
| Q4 2024 | -16.5% | -30.2% | -31.7% | |
| Q3 2024 | +2.6% | +3.2% | -2.9% | |
| Q2 2024 | -6.8% | -9.4% | -11.0% | |
| Q1 2024 | -0.5% | -6.8% | -23.9% | |
| Q4 2023 | +14.5% | +15.0% | +4.0% | |
| Q3 2023 | -3.1% | -11.1% | -3.7% | |
| Q2 2023 | +1.3% | +4.3% | +9.6% | |
| Q1 2023 | +12.7% | +10.3% | +7.3% | |
| Q4 2022 | +5.3% | -4.2% | -32.8% | |
| Q3 2022 | +2.7% | +10.6% | +14.3% | |
| Q2 2022 | +23.6% | +18.9% | +24.4% | |
| Q1 2022 | +8.5% | +21.8% | -6.1% | |
| Q4 2021 | +3.7% | -3.8% | -6.9% | |
| Q3 2021 | -9.2% | -15.7% | -31.7% | |
| Q2 2021 | -16.6% | -7.6% | -5.2% | |
| Q4 2020 | -16.6% | -7.6% | -5.2% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro